Drug Combination Details
| General Information of the Combination (ID: C98052) | |||||
|---|---|---|---|---|---|
| Name | Resveratrol NP Info | + | Rapamycin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
|
Bladder cancer
[ICD-11: 2C94]
|
Investigative | [2] | |||
|
Thyroid cancer
[ICD-11: 2D10]
|
Investigative | [3] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | KTC-1 | CVCL_6300 | Thyroid gland carcinoma | Homo sapiens | ||
| TPC-1 | CVCL_6298 | Thyroid gland papillary carcinoma | Homo sapiens | |||
| In-vivo Model | KTC-1 and TPC-1 cells in logarithmic growth phase were subcutaneously inoculated into the right armpit of Nude BALB/c mice (5*106 cells/mouse). | |||||
| Experimental
Result(s) |
Resveratrol sensitizes the anti-tumor effects of rapamycin and the PI3K/AKT/mTOR signaling is involved. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | EIF4B | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MUL1 | Molecule Info | |||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Wt MEFs | CVCL_L690 | Healthy | Mus musculus | ||
| HCV-29 | CVCL_8228 | Bladder carcinoma | Homo sapiens | |||
| 639V | CVCL_1048 | Ureter urothelial carcinoma | Homo sapiens | |||
| Ej138 | CVCL_2443 | Bladder carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
In combination with rapamycin, resveratrol was able to block rapamycin-induced Akt activation, while maintaining mTOR pathway inhibition. | |||||
| Experiment 3 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | EIF4B | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| MCF-10A | CVCL_0598 | Healthy | Homo sapiens | |||
| Experimental
Result(s) |
The combination of rapamycin and resveratrol is able to block upregulation of autophagy and induce apoptosis in breast cancer cells. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| BT-549 | CVCL_1092 | Invasive breast carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. | |||||
